logo
Share SHARE
FONT-SIZE Plus   Neg

St. Jude Announces First Implant In Trial Evaluating AMPLATZER Cardiac Plug

Medical device company St. Jude Medical Inc. (STJ) Friday announced the first patient implant in a new trial evaluating the company's AMPLATZER Cardiac Plug or ACP for the prevention of stroke. The company said the AMPLATZER Cardiac Plug Clinical Trial is designed to determine the safety and effectiveness of the ACP device in preventing blood clots from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke.

The implant was performed by Dr. Christian Machado, director of electrophysiology at the Providence Hospital Heart Institute, Southfield, Michigan, and investigator in the study.

Explaining the need for the trial, Dr. James Hermiller, an interventional cardiologist from St. Vincent Hospital in Indianapolis and ACP Trial investigator said, "The current standard of care for the prevention of stroke is warfarin or other oral blood-thinning medications that can be difficult for some people to tolerate, and may carry a risk of serious complications, such as bleeding.."

Commenting on the development, Frank Callaghan, president of the St. Jude Medical Cardiovascular and Ablation Technologies Division said, "The AMPLATZER Cardiac Plug has shown great promise in international markets and we look forward to establishing the evidence required to make it available in the U.S."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Monday reported strong U.S. vehicle sales for the month of July, driven by continued demand for trucks and sport-utility vehicles amid an improving economy, lower gas prices and easy availability of credit. Detroit's Big Three - General Motors Co., Ford Motor Co. and FCA US, LLC - all reported vehicle sales above analyst expectations. British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates.
comments powered by Disqus
Follow RTT